Search results
22 lis 2019 · The critical balance of oxygen in human cells is regulated by an intricate oxygen-sensing process in the body. When cancer cells hijack the process, they can fuel their own growth, and gain the ability to metastasize and resist chemotherapy and radiation treatment.
8 cze 2021 · HBOT increasing in oxygen partial pressure may benefit tumor suppression. In this study, we investigated the effects of HBOT on solid tumors, such as lung cancer.
High-flow oxygen therapy may be considered in selected patients for treatment of breathlessness, especially if they have hypoxaemic respiratory failure (II, B). A therapeutic trial for NIV can be considered in patients with cancer with severe chronic breathlessness, especially in patients with acute hypercapnic respiratory failure (II, B).
Tumor cells existing in such hypoxic environments have long been known to be resistant to anticancer therapy, display an aggressive phenotype, and promote tumor progression and dissemination. This review discusses the physiological basis of hypoxia, methods of detection, and strategies to overcome the resulting therapy resistance. The Oxygen Effect
3 sty 2020 · The role of oxygen therapy in end-of-life care for patients with advanced cancer is incompletely understood. We aimed to evaluate the association between oxygen use and survival in patients with advanced cancer and low oxygen saturation in home care.
26 cze 2018 · Lots of research has been conducted on hyperbaric oxygen’s use as a cancer treatment, often with mixed or inconclusive results. In 2015, scientists in Boston made headlines with a study that concluded flooding tumors with oxygen may help some therapies work better.
2 paź 2012 · Hyperbaric oxygen (HBO) treatment has for centuries been used to improve or cure disorders involving hypoxia and ischemia, by enhancing the amount of dissolved oxygen in the plasma and thereby increasing O 2 delivery to the tissue. Studies on HBO and cancer have up to recently focused on whether enhanced oxygen acts as a cancer promoter or not.
